The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells

Topical or systemic administration of JAK inhibitors has been shown to be a new treatment modality for severe alopecia areata (AA). Some patients show a good response to JAK inhibitors, but frequently relapse after cessation of the treatment. There have been no guidelines about the indications and use of JAK inhibitors in treating AA. The basic pathomechanism of AA and the relevant role of JAK inhibitors should support how to efficiently use JAK inhibitors. We sought to investigate the effect of JAK1/2 inhibitor on an in vitro model of AA and to examine the possible mechanisms. We used interferon gamma-pretreated human dermal papilla cells (hDPCs) as an in vitro model of AA. Ruxolitinib was administered to the hDPCs, and cell viability was assessed. The change of expression of the Wnt/β-catenin pathway, molecules related to the JAK-STAT pathway, and growth factors in ruxolitinib-treated hDPCs was also examined by reverse transcription PCR and Western blot assay. We examined immune-privilege-related molecules by immunohistochemistry in hair-follicle culture models. Ruxolitinib did not affect the cell viability of the hDPCs. Ruxolitinib activated several molecules in the Wnt/β-catenin signaling pathway, including Lef1 and β-catenin, and suppressed the transcription of DKK1 in hDPCs, but not its translation. Ruxolitinib reverted IFN-γ-induced expression of caspase-1, IL-1β, IL-15, and IL-18, and stimulated several growth factors, such as FGF7. Ruxolitinib suppressed the phosphorylation of JAK1, JAK2 and JAK3, and STAT1 and 3 compared to IFN-γ pretreated hDPCs. Ruxolitinib pretreatment showed a protective effect on IFN-γ-induced expression of MHC-class II molecules in cultured hair follicles. In conclusion, ruxolitinib modulated and reverted the interferon-induced inflammatory changes by blocking the JAK-STAT pathway in hDPCs under an AA-like environment. Ruxolitinib directly stimulated anagen-re-entry signals in hDPCs by affecting the Wnt/β-catenin pathway and promoting growth factors in hDPCs. Ruxolitinib treatment prevented IFN-γ-induced collapse of hair-follicle immune privilege.

[1]  Pietro Gentile,et al.  Advances in Regenerative Stem Cell Therapy in Androgenic Alopecia and Hair Loss: Wnt Pathway, Growth-Factor, and Mesenchymal Stem Cell Signaling Impact Analysis on Cell Growth and Hair Follicle Development , 2019, Cells.

[2]  J. E. Kim,et al.  Effects of mesenchymal stem cell therapy on alopecia areata in cellular and hair follicle organ culture models , 2020, Experimental dermatology.

[3]  A. Christiano,et al.  An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis. , 2018, The Journal of investigative dermatology.

[4]  B. King,et al.  Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients , 2017, Journal of the American Academy of Dermatology.

[5]  A. Christiano,et al.  Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. , 2016, JCI insight.

[6]  J. Ko,et al.  Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. , 2016, JCI insight.

[7]  K. Khosrotehrani,et al.  STAT5 Activation in the Dermal Papilla Is Important for Hair Follicle Growth Phase Induction. , 2016, The Journal of investigative dermatology.

[8]  A. Gottlieb,et al.  Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor , 2015, The British journal of dermatology.

[9]  A. Christiano,et al.  Pharmacologic inhibition of JAK-STAT signaling promotes hair growth , 2015, Science Advances.

[10]  Yoshiya Tanaka.  Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside. , 2015, Journal of biochemistry.

[11]  R. Mesa,et al.  Therapy for myeloproliferative neoplasms: when, which agent, and how? , 2014, Blood.

[12]  Y. Tokura,et al.  The role of cytokines and chemokines in the T‐cell‐mediated autoimmune process in alopecia areata , 2014, Experimental dermatology.

[13]  A. Christiano,et al.  Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition , 2014, Nature Medicine.

[14]  E. Fuchs,et al.  Transit-Amplifying Cells Orchestrate Stem Cell Activity and Tissue Regeneration , 2014, Cell.

[15]  Yoshiya Tanaka,et al.  JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical , 2013, Modern rheumatology.

[16]  Y. Shirakata,et al.  Hair‐inducing ability of human dermal papilla cells cultured under Wnt/β‐catenin signalling activation , 2012, Experimental dermatology.

[17]  R. Paus,et al.  Calcitonin gene‐related peptide (CGRP) may award relative protection from interferon‐γ‐induced collapse of human hair follicle immune privilege , 2012, Experimental dermatology.

[18]  J. Shapiro,et al.  Hair follicles from alopecia areata patients exhibit alterations in immune privilege-associated gene expression in advance of hair loss. , 2010, The Journal of investigative dermatology.

[19]  Ruth E. Baker,et al.  Cyclic dermal BMP signalling regulates stem cell activation during hair regeneration , 2008, Nature.

[20]  R. Paus,et al.  The hair follicle and immune privilege. , 2003, The journal of investigative dermatology. Symposium proceedings.

[21]  T. Wasserman,et al.  Use of a colorimetric microtiter (MTT) assay in determining the radiosensitivity of cells from murine solid tumors. , 1988, International journal of radiation oncology, biology, physics.